News | January 21, 2011

FDA Panel Recommends Conditional Approval for PET Agent

January 21, 2011 — The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee decided that it could not recommend approval of Amyvid (florbetapir) at this time based on the currently available data (13-3); but, voted unanimously (16-0) to recommend approval of Amyvid conditional on a reader training program that demonstrates reader accuracy and consistency through a re-read of previously acquired scans. The committee said efficacy was established and there were no significant safety concerns raised.

Amyvid is an imaging tool indicated for positron emission tomography (PET) imaging of beta-amyloid plaque in the brain. It is being investigated for the potential use in ruling out Alzheimer's disease. In addition to the pivotal phase III "Image-to-Autopsy" study, other clinical studies are also being conducted in the European Union., North and South America, Australia and Asia. The committee stated that a negative scan would be clinically useful in indicating that Alzheimer's pathology is unlikely to be the cause of a patient's cognitive decline.

Lilly acquired Avid Radiopharmaceuticals Inc. in December 2010. Amyvid is Avid's lead candidate and was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the United States. Amyvid was recently assigned priority review designation by the FDA.

The FDA will consider the panel's recommendation in its review of Amyvid. The FDA takes the advice of its advisory committees into consideration when reviewing investigational drugs, but is not bound by their recommendations.

For more information: www.lilly.com

Related Content

By eliminating the need to move neonates from the NICU to the radiology department, Aspect Imaging’s Embrace enables a safer way to perform the MRI procedure
News | Magnetic Resonance Imaging (MRI) | December 01, 2020
December 1, 2020 — Based on its recent analysis of the global neonatal intensive care unit magnetic resonance imaging
Resoundant Inc., announced hat it has entered into a strategic partnership with United Imaging Healthcare to begin offering advanced magnetic resonance elastography (MRE) on leading United Imaging MRI systems.
News | Magnetic Resonance Imaging (MRI) | November 30, 2020
November 30, 2020 — Resoundant Inc., announced hat it has entered into a strategic partnership with...
Up to one-third of women who sustain a fracture to the ulna bone of the forearm may be victims of intimate partner violence

X-ray shows fracture to the ulna bone of the forearm. Image courtesy of RSNA

News | Radiology Imaging | November 30, 2020
November 30, 2020 — Up to one-third of adult women who sustain a non-displaced fracture to the ulna bone of the forea
Researchers developed a deep learning model that identifies imaging biomarkers to predict a patient’s risk for developing breast cancer

A deep learning model was developed that combined imaging and traditional risk factors.

News | Mammography | November 30, 2020
November 30, 2020 — Researchers at Massachusetts General Hospi...
GE Healthcare unveiled a slate of new intelligently efficient solutions to help clinicians solve today’s two-part challenge of delivering high quality care while managing greater capacity and workflow issues, exacerbated by the impact of COVID-19.
News | Artificial Intelligence | November 30, 2020
November 30, 2020 — GE Healthcare unveiled a slate of new intelligently efficient solutions to help clinicians solve
The solution, presented at RSNA20, features image fusion and endovascular 3D navigation
News | Mobile C-Arms | November 30, 2020
November 30, 2020 — At this year's virtual RSNA congress,...